secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124543
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q3 2024 net loss $67.2M, cash $44.8M; BOT/BAL shows MSS CRC promise
--------------------------------------------------------------------------

- Cash $44.8M at Sept 30, 2024 (vs $76.1M Dec 2023); raised $7.1M via ATM post-quarter.
- Q3 2024 revenue $25.1M (non-cash); net loss $67.2M; cash used in ops 9M 2024 $129.7M (down from $183.8M YoY).
- BOT/BAL combination shows unprecedented outcomes in neoadjuvant MSS CRC (ESMO GI 2024) and advanced sarcomas (ESMO 2024).
- Strategic initiatives: real estate monetization discussions advancing; near-term transaction expected to deliver substantial resources.
- EMA agreement on dose selection and trial design for Phase 3 study in MSS CRC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024124543/0000950170-24-124543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024124543/agen-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer